Fact Source: Financial Supervisory Service DART / 2025-11-19
Disclosure Type: Relisting due to Corporate Split (Surviving Entity)
💡 3-Second Summary
Samsung Biologics has finalized its corporate split (surviving entity), reducing its total outstanding shares from 71,174,000 to 46,290,951, and the temporary trading halt on its stock will be officially lifted on November 24, 2025.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Listed Security: Samsung Biologics Common Stock
- Share Type and Count (Before → After): Registered Common Stock 71,174,000 shares → 46,290,951 shares (4th Issuance)
- Change in Number of Shares: -24,883,049 shares (reflecting the post-split surviving entity’s total)
- Par Value per Share: KRW 2,500
- Issuance Date: November 03, 2025 (4th Issuance of Registered Common Stock)
- Dividend Base Date: January 01, 2025
- Fiscal Year-End: December 31
- Relisting Date: November 24, 2025
- Reason for Change: Corporate Split (Surviving Entity)
- Trading Status: The suspension of trading for the company’s stock will be lifted on the relisting date (November 24, 2025).
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing indicates that Samsung Biologics has completed its corporate split execution, leading to an official adjustment of its capital base and outstanding shares on the stock exchange. This corporate action represents a structural shift in the company’s mid-to-long-term fundamental layout, reflecting the realignment of its business portfolio.
The most critical figure for investors to track is the contraction of the surviving entity’s share count, which dropped by approximately 24.88 million shares to a newly fixed 46,290,951 shares. Since the share count has altered, this structural adjustment could introduce initial trading volatility. It is important to note that this specific filing does not explain the concrete causes behind any earnings performance variations, nor does it specify the method of the split or detail the financial metrics of the split-off entity. Therefore, market participants should independently assess the changes in net asset value.
Crucially, the lifting of the trading suspension on November 24, 2025, marks the return of liquidity. The determination of the base price on the resumption day, along with shifting investor sentiment, may generate a potential impact characterized by widened price swings, meaning that a cautious approach is recommended.
📝 Editor’s Comment (by K-STOCK Editor)
The relisting of the surviving entity following Samsung Biologics’ corporate split will draw market attention, particularly as shareholder capital that has been locked up during the suspension becomes liquid once again. However, investors must look past the superficial reduction of 24.88 million shares. Short-term volatility could appear on the resumption day depending on where the initial opening price is established. Beyond the confirmed facts provided in this filing, the exact method of the split and the aggregate market capitalization trends remain to be judged objectively by the open market. This is a crucial juncture where investors should avoid getting swayed by premature optimism or pessimism, and instead focus strictly on the core fundamentals and value inherent to the surviving entity.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
